Stay updated on SENSITIZE: 4SC-202 + Pembrolizumab Clinical Trial

Sign up to get notified when there's something new on the SENSITIZE: 4SC-202 + Pembrolizumab Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the SENSITIZE: 4SC-202 + Pembrolizumab Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.2%
    Check dated 2024-06-13T22:38:28.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    4 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study details related to a Phase Ib/II clinical trial evaluating the combination treatment of 4SC-202 and Pembrolizumab in patients with unresectable or metastatic cutaneous melanoma primary refractory or non-responding to prior anti-PD-1 therapy.
    Difference
    0.2%
    Check dated 2024-06-06T14:49:23.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for patients with unresectable stage III or stage IV cutaneous melanoma, specifying health conditions and prior treatments required for participation. Previously, this section had no information provided.
    Difference
    21%
    Check dated 2024-05-22T21:37:54.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:39:53.000Z thumbnail image

Stay in the know with updates to SENSITIZE: 4SC-202 + Pembrolizumab Clinical Trial

Enter your email address, and we'll notify you when there's something new on the SENSITIZE: 4SC-202 + Pembrolizumab Clinical Trial page.